TheraLymph SIGNED
Gene Therapy to restore lymphatic flow lymphedema
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TheraLymph project word cloud
Explore the words cloud of the TheraLymph project. It provides you a very rough idea of what is the project "TheraLymph" about.
Project "TheraLymph" data sheet
The following table provides information about the project.
| Coordinator |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 8˙064˙946 € |
| EC max contribution | 8˙064˙946 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2019-Single-Stage-RTD |
| Funding Scheme | RIA |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2024-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR (PARIS) | coordinator | 1˙475˙531.00 |
| 2 | FLASH THERAPEUTICS | FR (TOULOUSE) | participant | 1˙132˙908.00 |
| 3 | HELSINGIN YLIOPISTO | FI (HELSINGIN YLIOPISTO) | participant | 1˙046˙198.00 |
| 4 | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE | FR (TOULOUSE CEDEX 3) | participant | 947˙000.00 |
| 5 | UNIVERSITE DE LAUSANNE | CH (LAUSANNE) | participant | 868˙185.00 |
| 6 | UNIVERSITE DE LIEGE | BE (LIEGE) | participant | 706˙250.00 |
| 7 | DE DUVE INSTITUTE | BE (BRUXELLES) | participant | 608˙335.00 |
| 8 | UPPSALA UNIVERSITET | SE (UPPSALA) | participant | 455˙000.00 |
| 9 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | FR (PARIS) | participant | 317˙287.00 |
| 10 | UNIVERZITA KARLOVA | CZ (PRAHA 1) | participant | 293˙750.00 |
| 11 | INSERM - TRANSFERT SA | FR (PARIS) | participant | 214˙500.00 |
Map
Project objective
Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substantially the quality of life. In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer. The main objective of Theralymph will be to establish a non-integrative gene therapy for this unmet medical need. The theralymph translational research program brings together bench scientists from 5 European countries and physicians from the hosted Rangueil hospital in which the PI institute is located to perform a Phase I/II trial focusing on women who developed lymphedema after breast cancer. Based on decades of disappointing results of monotherapy-gene delivery in cardiovascular diseases, our approach will be based on multiple gene therapy targeting both superficial lymphatic endothelium and deeper lymphatic collectors. We will identify molecules that possess a synergistic effect with the established lymphangiogenic factor VEGFC. Theralymph project will determine risk factors for lymphedema and cartography the lymphatic network in the pathology. It will decipher whether lymphatic intrinsic molecules or microenvironmental peptides or lipids are modified in the lymphedematous arm to promote the lymphatic dysfunction. Theralymph will validate the best molecule combination that restores the lymphatic drainage in in preclinical lymphedema models before human study. The Phase I/II gene therapy clinical trial will be performed in the vascular medicine department of Toulouse’s hospital, where the PI laboratory is located. This trial will use an innovative technology based on recently developed non-integrative lentiflash lentiviral vectors that allow a transient and highly efficient in vivo gene delivery.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERALYMPH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERALYMPH" are provided by the European Opendata Portal: CORDIS opendata.